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Abstract
Background: Burkholderia pseudomallei and Burkholderia mallei cause the diseases melioidosis and glanders,
respectively. A well-studied aspect of pathogenesis by these closely-related bacteria is their ability to invade and
multiply within eukaryotic cells. In contrast, the means by which B. pseudomallei and B. mallei adhere to cells are
poorly defined. The purpose of this study was to identify adherence factors expressed by these organisms.
Results: Comparative sequence analyses identified a gene product in the published genome of B. mallei strain
ATCC23344 (locus # BMAA0649) that resembles the well-characterized Yersinia enterocolitica autotransporter adhesin
YadA. The gene encoding this B. mallei protein, designated boaA, was expressed in Escherichia coli and shown to
significantly increase adherence to human epithelial cell lines, specifically HEp2 (laryngeal cells) and A549 (type II
pneumocytes), as well as to cultures of normal human bronchial epithelium (NHBE). Consistent with these findings,
disruption of the boaA gene in B. mallei ATCC23344 reduced adherence to all three cell types by ~50%. The
genomes of the B. pseudomallei strains K96243 and DD503 were also found to contain boaA and inactivation of
the gene in DD503 considerably decreased binding to monolayers of HEp2 and A549 cells and to NHBE cultures.
A second YadA-like gene product highly similar to BoaA (65% identity) was identified in the published genomic
sequence of B. pseudomallei strain K96243 (locus # BPSL1705). The gene specifying this protein, termed boaB,
appears to be B. pseudomallei-specific. Quantitative attachment assays demonstrated that recombinant E. coli
expressing BoaB displayed greater binding to A549 pneumocytes, HEp2 cells and NHBE cultures. Moreover, a
boaB mutant of B. pseudomallei DD503 showed decreased adherence to these respiratory cells. Additionally, a B.
pseudomallei strain lacking expression of both boaA and boaB was impaired in its ability to thrive inside J774A.1
murine macrophages, suggesting a possible role for these proteins in survival within professional phagocytic cells.
Conclusions: The boaA and boaB genes specify adhesins that mediate adherence to epithelial cells of the human
respiratory tract. The boaA gene product is shared by B. pseudomallei and B. mallei whereas BoaB appears to be a
B. pseudomallei-specific adherence factor.
Background
Burkholderia pseudomallei is a Gram-negative bacter-
ium readily recovered from the water and wet soils of
endemic areas bordering the equator, particularly South-
east Asia and Northern Australia [1-9]. The organism is
a motile, aerobic bacillus that can survive environmental
extremes as well as the bactericidal activities of comple-
ment [10-12], defensins [13-15], and phagocytes
[1,2,16-18]. The genome of the B. pseudomallei isolate
K96243 has been published by the Wellcome Trust San-
ger Institute and was shown to consist of two chromo-
somes of 4.1 and 3.2 Mbp [19]. Burkholderia mallei is a
non-motile, host-adapted clone of B. pseudomallei that
does not persist outside of its equine host and is ende-
mic to certain parts of Asia, Africa, the Middle East and
South America [8,9,20-25]. The genomic sequence of
the B. mallei strain ATCC23344 has been published by
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Mbp) than that of B. pseudomallei K96243. B. mallei
ATCC23344 was found to specify a large number of
mobile DNA elements that have contributed to exten-
sive deletions and rearrangements relative to the gen-
ome of B. pseudomallei K96243. Despite these
differences, the genes shared by the two isolates have an
average identity of 99% at the nucleotide level [19,26].
The genomic sequence of several B. pseudomallei and
B. mallei isolates are also publicly available through the
NCBI genomic BLAST service (http://www.ncbi.nlm.nih.
gov/sutils/genom_table.cgi), which provides a wealth of
resources to study these organisms.
B. pseudomallei causes the human disease melioidosis,
which is notoriously difficult to diagnose. Clinical manifes-
tations vary greatly and may present as flu-like symptoms,
benign pneumonitis, acute and chronic pneumonia, or ful-
minating septicemia. Infection occurs via inhalation of
contaminated aerosol particles or through skin abrasions,
and the risk of contracting the disease is proportional to
the concentration of B. pseudomallei in soil and water. In
endemic areas, heavy rainfalls result in a shift from percu-
taneous inoculation to inhalation as the primary mode of
infection, which leads to a more severe illness. Melioidosis
commonly affects the lungs and is characterized by the
spread of bacteria to various internal organs including the
spleen and liver. Many patients become bacteremic and
the mortality rate is high (19-51%) despite aggressive anti-
microbial therapy [1-9]. B. pseudomallei is refractory to
most antibiotics and resistance mechanisms include efflux
pumps and b-lactamases [27-36]. The recommended
treatment entails the use of ceftazidime, carbapenems,
TMP-SMZ, chloramphenicol and/or Augmentin for sev-
eral weeks. Response to treatment is slow and eradication
of B. pseudomallei is difficult to achieve, resulting in recru-
descence [1,37-39].
B. mallei causes the zoonosis glanders, which primar-
ily affects solipeds [8,9,20-25]. In humans, infection
occurs by contact with infected animals via the cuta-
neous or respiratory route. The clinical manifestations
of the disease include febrile pneumonia associated with
necrosis of the tracheobronchial tree or pustular skin
lesions and the development of abscesses. Most patients
become bacteremic and B. mallei disseminates to the
liver and spleen where it rapidly causes necrosis. Even
with antibiotic treatment, the mortality rate for human
glanders is 50% and the basis for this high mortality rate
is not understood, though B. mallei has been shown to
be resistant to complement-mediated killing [40],
macrophages [41] and antimicrobials [32,42].
One key aspect of pathogenesis by B. mallei and
B. pseudomallei is their ability to invade and multiply
within a variety of eukaryotic cells, where bacteria are
shielded from the host humoral immune response and
antibiotics. Once internalized, B. mallei and B. pseudo-
mallei escape from endocytic vacuoles and enter the
cytoplasm of infected cells where they multiply. The
organisms subsequently spread to neighboring cells
through a process involving the formation of actin tails
and membrane protrusions that push bacteria from one
cell to another. This intracellular lifestyle is crucial to
virulence and has been a focus of research efforts aimed
at understanding pathogenesis by B. mallei and B. pseu-
domallei [2,9,16-18,22,41,43-49]. Several gene products,
such as BimA, type 3 secretion system effectors, and
type 6 secretion proteins, have been shown to play key
r o l e si nt h i sp r o c e s s .B yc o n trast, the mechanisms used
by these organisms to adhere to eukaryotic cells are
poorly defined. Adherence is an essential step of patho-
genesis by most infectious agents because it is necessary
for colonizing a new host [50-52]. Moreover, B. pseudo-
mallei and B. mallei are facultative intracellular patho-
gens that gain access to the interior of target cells.
Though not always a prerequisite for this process, bac-
terial adherence is a widespread strategy that precedes
and promotes invasion [50-52]. Thus far, only the
B. pseudomallei flagellum [53] and type 4 pilus [54]
have been implicated in adherence and their exact roles
remain to be elucidated. The present study reports the
identification of B. pseudomallei and B. mallei gene pro-
ducts that mediate adherence to epithelial cells derived
from the human respiratory tract, thus relevant to the
aerosol route of infection by these organisms.
Results
Identification of a gene shared by B. mallei and B.
pseudomallei that encodes a potential autotransporter
adhesin
Analysis of the annotated genomic sequence of B. mallei
ATCC23344 identified the ORF locus tag number
BMAA0649 as resembling members of the oligomeric
coiled-coil adhesin (Oca) family of autotransporter pro-
teins [55]. Yersinia enterocolitica YadA [55-57] is the
prototypical member of this group of adherence factors,
which also includes Haemophilus influenzae Hia [58-60]
and Moraxella catarrhalis Hag [61,62]. These Oca pro-
teins share structural features including a C-terminal
outer membrane (OM) anchor domain composed of 4
b-strands (also referred to as the transporter module), a
surface-exposed passenger domain often containing
repeated amino acid (aa) motifs, and a helical region of
~40 residues that connects the OM anchor to the sur-
face-exposed passenger domain [55,63-65]. As illustrated
in Fig 1A, BMAA0649 is predicted to possess these fea-
tures. Further sequence analysis of the B. mallei
ATCC23344 gene product revealed that residues 208-
362 (and 1010-1149) contain repeats with the consensus
xxxAVAIGxx[N/A]xAx (open circles in Fig 1A), which
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litica YadA (xxxSVAIGxxSxAx) [56,57] and M. catar-
rhalis Hag (GxxSIAIGxx[A/S]xAx) [61]. In YadA, these
AIG patterns have been shown to form a structure
termed a b-roll and to specify adhesive properties. The
passenger domain of BMAA0649 was also found to con-
tain several serine-rich repeats beginning with residues
SLST (colored squares in Fig 1A). Additionally, searches
using the Pfam database indicated that aa 1456-1535 of
BMAA0649 encode a YadA-like C-terminal domain
(PF03895; expect value 3.8 e
-11), which is present in
most Oca molecules and is described as important for
oligomerization. Taken together, these observations sug-
gest structural and functional similarities between
BMAA0649 and members of the Oca family of autotran-
sporters. Hence, we designated this ORF of B. mallei
Figure 1 Structural features of the boaA and boaB gene products. Different regions of the predicted B. mallei ATCC23344 BoaA (A),
B. pseudomallei K96243 BoaA (B) and B. pseudomallei K96243 BoaB (C) proteins are depicted with the positions of residues defining selected
domains. The horizontal brackets outline selected regions of the BoaA and BoaB proteins and the percent identity between these regions is
shown below the brackets. Transporter modules (OM anchors) and helical linkers were identified using the PSIPRED secondary structure
prediction algorithm. The colored boxes show the relative position and number of repeated SLST motifs.
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Table 1 lists characteristics of the boaA gene and its
encoded product.
The published genome of B. pseudomallei K96243 was
also found to specify a boaA gene product (BPSS0796,
Fig 1B) that is 92.7% identical to that of B. mallei
ATCC23344. Oligonucleotide primers were designed to
amplify the entire boaA gene from the B. pseudomallei
strain used in our laboratory, DD503, and sequence ana-
lysis of this amplicon predicted a gene product that is
94.4% and 90.6% identical to BoaA of B. mallei
ATCC23344 and B. pseudomallei K96243, respectively.
Database searches with the NCBI genomic BLAST ser-
vice also identified boaA in several B. pseudomallei and
B. mallei isolates. All nine B. mallei and 23 B. pseudo-
mallei strains for which sequences are available through
this service were found to have the gene. Characteristics
of some of these ORFs are listed in Tables 1 and 2.
Overall, the BoaA proteins are 82-94% identical and dif-
f e rp r i m a r i l yi nt h en u m b e ra n d / o ra r r a n g e m e n to f
SLST repeats in their predicted passenger domains (data
not shown). Based on these results, we conclude that
BoaA is a well-conserved gene product shared by B.
mallei and B. pseudomallei.
Identification of a B. pseudomallei-specific gene encoding
a putative autotransporter adhesin that resembles BoaA
Further analysis of the annotated genomic sequence of
B. pseudomallei K96243 identified the ORF locus tag
number BPSL1705 as specifying a second Oca-like pro-
tein that is ~60% identical to BoaA. The last 776 aa of
BPSL1705 and BoaA are 82.5% identical (Fig 1) and the
very last 93 residues, which encompass the predicted
C-terminal OM-anchoring domain and a-helical region
Table 1 Characteristics
a of boaA and boaB genes and their encoded products
Strain Gene Chromosome Locus tag GenBank accession
#
ORF
(nt)
Predicted
protein
(aa)
MW
(Da)
Potential signal
sequence
cleavage site
b
B.mallei
ATCC23344 boaA 2 BMAA0649 YP_105401.1 4608 1535 140,689 WA
18▼GV
NCTC10247 boaA 2 BMA10247_A1776 YP_001078959.1 5301 1766 162,744 WA
77▼GV
B. pseudomallei
K96243 boaA 2 BPSS0796 YP_110805.1 4962 1653 151,565 WA
18▼GV
DD503 boaA ND - EF423807 4680 1559 143,209 WA
18▼AL
1710b boaA 2 BURPS1710b_A2381 YP_337531.1 4881 1626 149,383 WA
10▼AL
K96243 boaB 1 BPSL1705 YP_108306.1 4821 1606 148,811 VA
23▼GT
DD503 boaB ND - EF423808 4965 1654 154,117 VA
71▼GT
1710b boaB 1 BURPS1710b_2168 YP_333563.1 4965 1654 154,059 VA
71▼GT
aSequence analyses were performed using Vector NTI (Invitrogen) and online tools available through the ExPASy Proteomics Server.
bThe putative signal sequence cleavage site was determined using the SignalP 3.0 server.
ND = not determined.
Table 2 Percent identity shared by boaA and boaB gene products
BoaA (Bm
ATCC23344)
BoaA (Bm
NCTC10247)
BoaA (Bp
K96243)
BoaA (Bp
DD503)
BoaA (Bp
1710b)
BoaB (Bp
K96243)
BoaB (Bp
DD503)
BoaB (Bp
1710b)
BoaA (Bm
ATCC23344)
100
BoaA (Bm
NCTC10247)
86.9 100
BoaA (Bp
K96243)
92.7 89.2 100
BoaA (Bp
DD503)
94.4 82.2 90.6 100
BoaA (Bp 1710b) 90.4 83.1 92.4 93.6 100
BoaB (Bp
K96243)
64 60 65 63.9 63.9 100
BoaB (Bp
DD503)
62 60.8 62.9 61.9 62.2 96.7 100
BoaB (Bp 1710b) 62.2 60.9 63.2 62.1 62.4 97 99.7 100
Bm = B. mallei.
Bp = B. pseudomallei.
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served (94.7% identity, Fig 1 and 2). The BPSL1705 ORF
is predicted to encode a protein of 148-kDa which, as
depicted in Fig 1C, possesses many of the structural fea-
tures observed in BoaA including two sets of b-roll AIG
motifs with the consensus xxG(S/A)(V/I)AIGxx(N/A)
xAx and several SLST repeats. This high level of
sequence and structural similarity between BPSL1705
and BoaA prompted us to designate this B. pseudomallei
K96243 gene product BoaB.
The boaB gene was sequenced from B. pseudomallei
DD503 and was predicted to encode a protein that is
96.7% identical to BoaB of B. pseudomallei K96243.
Database searches using NCBI genomic BLAST revealed
that the genomes of at least 10 more B. pseudomallei
strains contain the gene. Overall, the BoaB proteins are
highly-conserved (90-99% identity) and characteristics of
the ORF from selected strains are shown in Tables 1
and 2 and Fig 2 for comparison purposes. Importantly,
database searches also revealed that none of the B. mal-
lei isolates available through the NCBI genomic BLAST
service have a boaB gene. Taken together, these results
indicate that BoaB is a highly-conserved B. pseudomal-
lei-specific molecule.
Expression of the Burkholderia BoaA and BoaB proteins in
E. coli
Because of their sequence and structural similarities to
known bacterial adhesins, we hypothesized that BoaA
and BoaB mediate adherence to human epithelial cells.
To test this hypothesis, the B. mallei ATCC23344 boaA
and B. pseudomallei DD503 boaB genes were cloned
into the E. coli strain EPI300. This organism does not
normally adhere well to human epithelial cells [61,62,66]
and therefore provides an appropriate heterologous
genetic background for examining the adhesive proper-
ties of BoaA and BoaB. To verify gene expression, RNA
was prepared from E. coli harboring the plasmids pCC1.3
(control), pSLboaA (specifies B. mallei ATCC23344
boaA) and pSLboaB (specifies B. pseudomallei DD503
boaB), and analyzed by quantitative Reverse-Transcrip-
tase PCR (qRT-PCR). Fig 3A demonstrates that the boaA
and boaB genes are expressed by recombinant bacteria
and that the primers used in these experiments are speci-
fic for their corresponding genes. Sarkosyl-insoluble OM
proteins were also extracted from E. coli cells and ana-
lyzed by western blot to ensure production of the Bur-
kholderia proteins. Fig 3B shows that a-BoaA antibodies
(Abs) react with a band of 130-kDa in the OM of E. coli
expressing boaA (lane 3) whereas Abs against BoaB bind
to a 140-kDa antigen in E. coli expressing boaB (lane 5).
These molecular weights (MWs) are consistent with the
predicted masses of the gene products (Table 1).
In addition to showing that BoaA and BoaB are asso-
ciated with the OM by protein separation and western
blot, we used immunofluorescent labeling of non-
permeabilized E. coli cells to demonstrate their display
on the bacterial surface. As depicted in Fig 3C, E. coli
harboring pSLboaA and pSLboaB are labeled by the
a-BoaA and a-BoaB Abs, respectively, while recombi-
nant bacteria carrying the control plasmid pCC1.3 are
not. Staining of nucleic acids with the fluorescent dye
DAPI verified that comparable numbers of bacterial
cells were examined (Fig 3C). Quantitative attachment
assays revealed that E. coli expressing BoaB attach to
HEp2 (laryngeal) and A549 (type II pneumocytes)
epithelial cell lines at levels 18- and 68-fold greater than
bacteria carrying pCC1.3, respectively (Fig 3D). In addi-
tion, BoaB expression was found to increase adherence
to differentiated primary cultures of normal human
bronchial epithelium (NHBE). Under the growth condi-
tions used, NHBE cultures form a pseudostratified
epithelium with tight junctions containing both ciliated
and non-ciliated cells. This epithelium exhibits transe-
pithelial resistance, mucus secretion, mucociliary activ-
ity, and an apical surface not submerged in tissue
culture medium, thus representing an environment that
is similar to the airway lumen in vivo [67-69]. Expres-
sion of the B. mallei ATCC23344 BoaA protein on the
surface of E. coli also substantially increased adherence
to monolayers of A549 and HEp2 cells and to NHBE
cultures. Taken together, these data demonstrate that
BoaA and BoaB are OM proteins mediating adherence
to epithelial cells of the human respiratory tract.
Figure 2 Sequence comparison of boaA and boaB gene products. The last 93 residues of selected boaA and boaB gene products are shown
with the positions of the aa defining these regions in parentheses. Perfectly conserved aa are shown in black text over white background.
Residues unique to BoaA proteins are shown in blue text over a yellow background. Residues unique to BoaB proteins are shown in white text
over a blue background. Bm = B. mallei, Bp = B. pseudomallei.
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lular organisms that can invade, survive and replicate in
a variety of eukaryotic cells. Moreover, autotransporter
adhesins often specify additional biological functions
such as invasion [70], biofilm formation [71], survival
within host cells [72] and intracellular motility [16]. For
these reasons, we measured the ability of E. coli expres-
sing BoaA and BoaB to invade epithelial cells as well as
their ability to survive within murine macrophages. We
also measured the ability of these recombinant strains to
form biofilms on the plastic support of tissue culture
plates using a crystal violet-based assay. The results of
these experiments indicated that neither BoaA nor BoaB
substantially increase invasion of epithelial cells, phago-
cytosis of recombinant bacteria by J774A.1 murine
macrophages, survival inside these immune cells, or bio-
film formation (data not shown).
Construction and characterization of Burkholderia mutant
strains
To study the functional properties of the boa gene pro-
ducts in the native Burkholderia background, we con-
structed isogenic boaA mutants of B. pseudomallei
DD503 and B. mallei ATCC23344 as well as an isogenic
boaB mutant of B. pseudomallei DD503. A double
mutant strain was also engineered in which inactivated
versions of both boaA and boaB were introduced in the
genome of B. pseudomallei DD503. Whole cell lysates
and sarkosyl-insoluble OM proteins were prepared from
these strains and analyzed by western blot to verify lack
Figure 3 Analysis of recombinant E. coli strains. Panel A: Total RNA was isolated from E. coli strains, reverse-transcribed to cDNA, and the
relative levels of boaA or boaB transcript were determined by qRT-PCR. Each bar represents 4 different samples collected on 2 separate
occasions. The Y-axis corresponds to the levels of boaA or boaB transcript normalized to recA and the error bars correspond to the standard
error. Negative controls in which the reverse transcriptase enzyme was not added to reaction mixtures were included in all experiments (data
not shown). Panel B: Proteins present in Sarkosyl-insoluble OM protein preparations were resolved by SDS-PAGE, transferred to PVDF membranes
and analyzed by western blot with antibodies against BoaA (lanes 1-3) or BoaB (lanes 4-6). Lanes 1 & 4, E. coli (pCC1.3); lanes 2 & 5, E. coli
(pSLboaB); lanes 3 & 6, E. coli (pSLboaA). MW markers are shown to the left in kilodaltons. Panel C: Non-permeabilized E. coli strains were fixed
onto glass slides and fluorescently-labeled with DAPI (blue) and with a-BoaA or a-BoaB antibodies (red). Bacteria were visualized by microscopy
using a Zeiss LSM 510 Meta confocal system. Representative microscopic fields are shown. Panel D: E. coli strains were incubated with A549 and
HEp2 cells for 3-hr and with NHBE cultures for 6-hr. Epithelial cells were washed to remove unbound bacteria, lysed, diluted, and spread onto
agar plates to enumerate bound bacteria. The results are expressed as the mean percentage (± standard error) of inoculated bacteria adhering
to epithelial cells. Asterisks indicate that the increased adherence of the indicated strains, compared to E. coli carrying the control plasmid
pCC1.3, is statistically significant (P < 0.05). These attachment assays were performed in duplicate on at least 3 separate occasions.
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a-BoaA and a-BoaB Abs, however, did not react with
Burkholderia protein preparations (data not shown). In
order to determine whether the genes are expressed,
total RNA was isolated from B. pseudomallei DD503
and B. mallei ATCC23344 and the relative transcript
levels of boaA and boaB were assessed by qRT-PCR. Fig
4s h o w st h a tboaA and boaB are expressed by B. pseu-
domallei while B. mallei only expresses boaA,w h i c hi s
in agreement with database searches revealing that B.
mallei isolates do not contain a boaB gene. The qRT-
PCR data also demonstrate that the genes are expressed
at very low levels compared to Burkholderia recA, which
was used to normalize boaA and boaB transcript levels.
These results are consistent with our inability to visua-
lize the proteins by western blot. Other methods such
as immunoprecipitation and immunofluorescence label-
ing also proved unsuccessful at detecting production of
BoaA and BoaB by Burkholderia strains.
Quantitative attachment assays with recombinant
bacteria indicated that BoaA or BoaB expression signif-
icantly increases the adherence of E. coli to monolayers
of A549 and HEp2 cells and to NHBE cultures
(Fig 3D). We therefore compared the ability of
Burkholderia parent and boa mutant strains to attach
to these respiratory cells. As shown in Fig 5A and 5D,
inactivation of the boaA gene in B. mallei ATCC23344
and B. pseudomallei DD503 decreases adherence to
A549 cells by 60 and 53%, respectively. The boaA
mutation also caused a 50% reduction in the binding
of B. pseudomallei to HEp2 monolayers (Fig 5B), and
reduced adherence of B. mallei to these laryngeal cells
by 67% (Fig 5E). Moreover, both boaA mutant strains
displayed significant impairment in their abilities to
attach to NHBE cultures (Fig 5C and 5F). The boaB
mutation in B. pseudomallei DD503 decreased attach-
ment to A549 and HEp2 cells by ~50% (Fig 5A and
5B, respectively) and caused a 62% reduction in adher-
ence to NHBE cultures (Fig 5C). As expected, the dou-
ble mutant strain DD503.boaA.boaB exhibited
significantly lower attachment to epithelial cells com-
pared to the parent strain DD503 (Fig 5A, B, and 5C).
T h ea d h e r e n c el e v e l so ft h ed o u b l em u t a n t ,h o w e v e r ,
did not differ significantly from that of the single
mutants in any of the cell types tested. One possible
explanation for this apparent lack of synergistic effect
is that other adhesins expressed by the double mutant
strain DD503.boaA.boaB provide a high background
level of adherence. Taken together, these results
demonstrate that the boaA and boaB gene products
contribute to the adherence of B. mallei and B. pseu-
domallei to epithelial cells of the human respiratory
tract.
As previously stated, autotransporter adhesins often
specify additional biological functions including survival
within host cells [72]. In addition, B. pseudomallei and
B. mallei are facultative intracellular pathogens that are
particularly proficient at replicating inside professional
phagocytic cells. For these reasons, we measured the
ability of our panel of Burholderia mutant and parent
strains to replicate within J774A.1 murine macrophages.
In B. pseudomallei DD503, inactivation of the boa genes
had no effect on phagocytosis of the organism (Fig 6A).
Once inside macrophages, the boaA (DD503.boaA) and
boaB (DD503.boaB) single mutants replicated at rates
equivalent to that of the progenitor strain DD503 (Fig
6B). However, when both boaA and boaB genes were
disrupted (DD503.boaA.boaB), intracellular growth was
diminished by 60% (Fig 6B). To verify that this reduced
intracellular fitness was not due to a global growth
defect, we measured the growth of strains DD503 and
DD503.boaA.boaB in broth as well as in tissue culture
medium. We found that both strains grew at equivalent
rates under both conditions (data not shown). Interest-
ingly, the double mutant did not exhibit a growth defect
in epithelial cells (data not shown). These results suggest
a role for the BoaA and BoaB proteins in B. pseudomal-
lei’s ability to grow inside professional phagocytes. No
Figure 4 Quantitative reverse-transcriptase PCR analysis of B.
mallei and B. pseudomallei strains. Total RNA was isolated from B.
pseudomallei (Bp) DD503 and B. mallei (Bm) ATCC23344, reverse-
transcribed to cDNA, and the relative levels of boaA or boaB
transcript was determined by qRT-PCR. Each bar represents 4
different samples collected on 2 separate occasions. The Y-axis
corresponds to levels of boaA or boaB transcript normalized to recA
and the error bars correspond to the standard error. A primer set
for Borrelia burgdorferi recA was used as a control to further
demonstrate primer specificity (see bars labeled as control). Of note,
negative controls in which the reverse transcriptase enzyme was
not added to reaction mixtures were included in all experiments
and the results were equivalent to the Borrelia burgdorferi controls
(data not shown).
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for the B. mallei ATCC23344 boaA mutant strain (data
not shown). It should also be noted that none of the
boa mutants showed decreased biofilm formation on the
plastic support of tissue culture plates nor defects in
resistance to the bactericidal activity of normal human
serum (data not shown), both biological functions that
are also commonly associated with Oca autotransporter
adhesins [56,63,73-75].
Discussion
Autotransporters are involved in various biological traits
of Gram-negative bacteria including invasion [70], serum
resistance [56,73], phospholipolysis [76,77], cyto-
toxicity [78], adherence [61,79], biofilm formation
[71,80], survival within eukaryotic cells [72] and intracel-
lular motility [16]. These proteins share an N-terminal
extracellular passenger domain that specifies the biologi-
cal activity of the autotransporter and a C-terminus con-
taining several b-strands, which tether the molecule to
the OM. Based on the structure of this membrane-
anchoring domain, autotransporters can be classified as
conventional (contain 12 b-strands) or trimeric (contain
4 b-strands) [65]. One of the best characterized trimeric
autotransporters is the Y. enterocolitica adhesin YadA.
This protein, along with structurally-related adherence
Figure 5 Adherence of B. mallei and B. pseudomallei strains to human respiratory epithelial cells. The effects of boaA and boaB mutations
on the adherence of B. pseudomallei (Bp) DD503 and B. mallei (Bm) ATCC23344 to monolayers of A549 (panels A and D) and HEp2 (panels B and
E) cells and cultures of NHBE (panels C and F) was measured in duplicate on at least 3 separate occasions. The results are expressed as the
mean percentage (± standard error) of inoculated bacteria adhering to epithelial cells. Asterisks indicate that the difference between the
adherence of the mutant and that of the parental strain is statistically significant (P < 0.05).
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Page 8 of 19Figure 6 Uptake and growth of B. pseudomallei strains in J774A.1 murine macrophages. J774A.1 cells (duplicate wells in each of two 24-
well tissue culture plates) were infected with B. pseudomallei strains at an MOI of 10 and incubated for 1-hr to allow phagocytosis of the
organisms. Following incubation, the monolayers were incubated for 2-hr in medium containing gentamicin to kill extracellular bacteria. After
gentamicin treatment (i.e. 3-hr post infection), the wells of one plate were washed, lysed, serially diluted, and spread onto agar plates to
determine the number of bacteria phagocytosed by macrophages. The results of this first part of the experiments (i.e. bacterial uptake) are
shown in panel A and are expressed as the percentage of bacteria (± standard error) used to infect macrophages that were phagocytosed. The
wells of the other tissue culture plate inoculated with B. pseudomallei strains were washed once, fresh medium without antibiotics was added to
wells, and the plate was incubated for an additional 5-hr. Following this incubation (i.e. 8-hr post-infection), the wells were processed as
described above in order to enumerate bacterial numbers. The results of this second part of the experiments (i.e. intracellular growth of
phagocytosed bacteria) are shown in panel B and are expressed as a growth/uptake ratio (± standard error) obtained by dividing the number of
bacteria/well at 8-hr post infection by the number of bacteria/well at the 3-hr post infection time point. These experiments were repeated on at
least 3 separate occasions. The asterisk indicates that the difference between the intracellular growth of the double mutant strain DD503.boaA.
boaB and that of its parent isolate DD503 is statistically significant (P < 0.05). Panel C shows the total number of bacteria in the inoculum (grey
bars), the number of phagocytosed bacteria (open bars, 3-hr post infection) and the total number of bacteria/well at the end point of the
experiment (black bars, 8-hr post infection).
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Hia, are often referred to as oligomeric coiled-coil
adhesins (Oca) [55].
Tiyawisutsri and colleagues previously reported that
the published genomic sequences of B. pseudomallei
K96243 and B. mallei ATCC23344 contain several ORFs
encoding putative trimeric autotransporters [81]. Of
these, only BimA (i.e. B. pseudomallei and B. mallei
locus tag numbers BPSS1492 and BMAA0749, respec-
tively) has been functionally characterized and shown to
be required for actin-based motility of the organisms
inside eukaryotic cells [16,17]. In the present study, we
identified the boaA ORF based on similarities to the
Oca proteins Y. enterocolitica YadA and M. catarrhalis
Hag. Specifically, we searched the genome of B. mallei
ATCC23344 for gene products specifying N-terminal
AIG b-roll motifs, a transporter module containing
4 b-strands, and a YadA-like C-terminal domain
(PF03895). We demonstrated that when expressed by E.
coli, boaA increases adherence to the human epithelial
cell lines HEp2 (laryngeal cells) and A549 (type II pneu-
mocytes) grown as monolayers in submerged cultures.
Though these cell types are relevant to the aerosol route
of infection by B. mallei and B. pseudomallei, they lack
important features of the airway mucosa such as cilia
and mucociliary activity. The ciliated cells of the respira-
tory tract and other mucosal membranes keep secretions
moving and contribute to preventing colonization by
pathogens. For these reasons, we also measured the
adherence of E. coli expressing BoaA to cultures of nor-
mal human bronchial epithelium (NHBE) grown in an
air-liquid interface system. These cultures mimic the
structure and function of the airway mucosa more accu-
rately as they are fully differentiated, form a pseudostra-
tified epithelium with tight junctions, contain ciliated
and mucus-producing goblet cells, and exhibit mucocili-
ary activity [67-69]. Quantitative attachment assays uti-
lizing this culture system revealed that BoaA expression
increases adherence to NHBE cultures (Fig 3D).
In addition to showing that BoaA specifies adhesive
properties when expressed in the heterologous genetic
background of E. coli, we determined that disruption of
the boaA gene in the genome of B. mallei ATCC23344
reduces adherence of the organism to monolayers of
HEp2 and A549 cells and to NHBE cultures, therefore
substantiating the function of BoaA as an adhesin. Data-
base searches using the NCBI genomic BLAST service
identified boaA in several B. pseudomallei and B. mallei
isolates and we demonstrated that inactivation of boaA
in the B. pseudomallei strain DD503 also decreases
attachment to HEp2 laryngeal cells, A549 pneumocytes,
and NHBE cultures. Together, our data indicate that
BoaA is an adhesin common to B. mallei and B. pseudo-
mallei and mediates adherence to host cells relevant to
pathogenesis by the organisms. These findings are con-
sistent with the recent inclusion of BoaA (i.e. B. mallei
ATCC23344 and B. pseudomallei K96243 locus tag
numbers BMAA0649 and BPSS0796, respectively) in the
virulome of B. mallei and B. pseudomallei, which con-
sists of a set of 650 putative virulence genes that are
shared by B. pseudomallei and B. mallei but are not pre-
sent in five closely-related non-pathogenic Burkholderia
species [82].
Comparative genomic analyses revealed that several B.
pseudomallei isolates possess a second Oca-like gene
product highly similar to BoaA, which we termed BoaB.
The C-terminus of BoaB is strikingly similar to that of
BoaA (Fig 2) and the predicted passenger domains of
the molecules contain numerous matching serine-rich
SLST motifs (Fig 1). The proteins are also functionally
related as they mediate adherence to the same types of
host cells (Fig 3D and 5). Therefore, it is tempting to
speculate that boaA and boaB are the result of gene
duplication. This hypothesis would be consistent with
the genomic organization of the genes. In B. pseudomal-
lei strains K96243, 1710b, 1655, 576 and MSHR346, the
boaB gene is located on chromosome 1 while boaA is
on chromosome 2. Moreover, the boaB gene in all these
isolates is preceded by two ORFs specifying an invertase
and a transposase. These genes may be the remnants of
mobile genetic elements possibly involved in gene dupli-
cation. Database searches also revealed that B. mallei
isolates do not possess a boaB gene, which was likely
lost during evolution of the organism into a host-
adapted pathogen. Interestingly, the closely-related bac-
terium Burkholderia thailandensis has been reported by
others to bind poorly to epithelial cells [83]. This organ-
ism exhibits high genomic similarities to B. pseudomal-
lei and B. mallei and, like B. pseudomallei,i san a t u r a l
inhabitant of the tropical soil environment. However, B.
thailandensis is not considered pathogenic to humans
or higher animals [84-87]. This difference in virulence
can be attributed to the fact that B. thailandensis does
not produce a capsule [88] and lacks the 650 genes
comprising the aforementioned virulome of B. mallei
and B. pseudomallei. Analysis of the published genome
of the B. thailandensis strain E264 [89] indicated that it
contains neither the boaA nor the boaB gene.
B. pseudomallei DD503 and B. mallei ATCC23344 do
not produce detectable amounts of the BoaA and BoaB
proteins under the conditions tested. These results are
consistent with qRT-PCR experiments demonstrating
that the organisms express very low levels of the boa
genes relative to the Burkholderia recA control (Fig 4).
Similar observations were made by Druar and colleagues
while studying expression of the Burkholderia Type 3
Secretion System-3 (T3SS-3) proteins BipB and BipD
[90]. These proteins were not detected in lysates of
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ditions, even though the antibodies used in their western
blot experiments recognized recombinant forms of BipB
and BipD. The authors concluded that these two T3SS-
3 molecules must be expressed in detectable amounts
only under very specific in vitro conditions [90]. Using a
gfp reporter strain, Burtnick et al recently showed that
the B. mallei Type 6 Secretion System-1 (T6SS-1) gene
tssE is not expressed at detectable levels when bacteria
are grown in LSLB or tissue culture medium, but is
expressed upon phagocytosis of the organisms by mur-
ine macrophages [49]. The protein preparations tested
in our studies were obtained from bacteria cultured on
LSLB agar plates at 37°C, conditions which may not be
optimal for expression of the BoaA and BoaB proteins.
Additionally, Chantratita and colleagues reported that
growth of B. pseudomallei under various conditions trig-
gers a complex adaptive process altering the expression
of surface molecules [91]. This process, termed phenoty-
pic plasticity, was correlated with changes in the mor-
phology of B. pseudomallei colonies grown on agar
plates and appears to modulate the environmental fit-
ness, as well as virulence, of the organism. Given their
surface location and likely role in virulence (i.e. adher-
ence to host cells), it is possible that BoaA and BoaB are
subject to phenotypic plasticity and are expressed in
detectable amounts only under very specific in vitro
conditions. In concordance, the reduced adherence phe-
notype of the boaA and boaB mutant strains suggests
increased level of expression of the genes when Burkhol-
deria is incubated with epithelial cells. However, efforts
to detect protein expression under these conditions (i.e.
immunofluorescence, immunoprecipitation) have been
unsuccessful. Of further note, studies have shown that
sera from horses infected with B. mallei and sera from
melioidosis patients contain antibodies reacting with
BoaA (i.e. B. mallei ATCC23344 locus tag number
BMAA0649) [81] and with BoaB (i.e. B. pseudomallei
K96243 locus tag number BPLS1705) [92], respectively,
which indicates expression of the autotransporters in
vivo. Determining the conditions and mechanisms that
modulate expression of the Boa adhesins, and their
influence on the binding of B. pseudomallei and B. mal-
lei to host surfaces, represent key areas for future study.
Disruption of boaA and boaB in the B. pseudomallei
double mutant strain DD503.boaA.boaB was found to
h a v eas i g n i f i c a n te f f e c to nt h eg r o w t ho ft h eo r g a n i s m
within murine macrophages (Fig 6B). At present, it is
not clear whether BoaA and BoaB play a direct role in
intracellular replication. It is possible that the absence of
both Boa proteins in the OM of DD503.boaA.boaB
affects the proper surface display of another molecule
involved in this phenotypic trait. One candidate is LPS,
as this molecule was previously shown to play an
important role in the ability of B. pseudomallei to grow
inside host cells [93,94]. B. pseudomallei produces mul-
tiple T3SS and T6SS that are involved in the intracellu-
lar lifestyle of the organism. These specialized secretion
apparatuses are used to inject bacterial effector proteins
inside host cells where they exert cytopathic effects or
manipulate signaling pathways. One important step in
this process is the proper docking of bacteria to the
host cell to deliver the effectors. Given their roles in
adherence, it is possible that the lack of expression of
the boaA and boaB gene products interferes with the
delivery of T3SS and/or T6SS cell-altering effectors,
which in turn reduces the intracellular fitness of the
double mutant strain DD503.boaA.boaB. The Yersinia
pestis OM adhesin Ail was recently shown to affect
delivery of Yop effector proteins to HEp2 cells and
macrophages in such a manner [95]. Alternatively, the
reduced intracellular growth of the double boaA boaB
mutant may be due to a greater sensitivity to immune
effectors produced by the macrophages. The molecular
basis for this phenotype is currently being investigated.
Conclusion
The present study reports the identification of B. pseu-
domallei and B. mallei gene products mediating adher-
ence to epithelial cells. Because of their classification as
select agents, there is currently a shortage of tools for
genetic studies in B. pseudomallei and B. mallei (i.e.
paucity of acceptable antibiotic markers, lack of low
copy plasmids suitable for expressing surface proteins),
which precluded us from complementing mutants. Our
ability to express BoaA and BoaB in E. coli,h o w e v e r ,
conclusively demonstrates that the proteins directly
mediate binding to epithelial cells. These results, along
with our analyses of the mutant strains, clearly establish
that these molecules participate in adherence by B. pseu-
domallei and B. mallei. Adherence is an essential step in
pathogenesis by most infectious agents because it is
necessary for colonization and precedes invasion of host
cells by intracellular pathogens. Thus, continued investi-
gation of BoaA and BoaB will yield important informa-
tion regarding the biology and virulence of these
organisms.
Methods
Strains, plasmids, tissue culture cell lines and growth
conditions
The strains and plasmids used in this study are described
in Table 3. B. pseudomallei and B. mallei were routinely
cultured at 37°C using Low Salt Luria Bertani (LSLB)
agar (Teknova) supplemented with polymyxin B [PmB]
(100 μg/ml for B. pseudomallei;7 . 5μg/ml for B. mallei),
zeocin (100 μg/ml for B. pseudomallei;7 . 5μg/ml
for B. mallei), kanamycin [Kan] (50 μg/ml for B.
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(used only for B. pseudomallei,1 0 0 0μg/ml) and glycerol
(used only for B. mallei, 5%), where indicated. Plate-
grown bacteria (20-hr growth for B. pseudomallei; 40-hr
growth for B. mallei) were used for extraction of Sarko-
syl-insoluble outer membrane proteins, preparation of
whole cell lysates, RNA isolation, as well as for adher-
ence, invasion, bactericidal, biofilm, and macrophage
assays.
E. coli was cultured using LSLB containing 15 μg/ml
chloramphenicol, 50 μg/ml Kan or 50 μg/ml zeocin,
where indicated. For preparation of plasmid DNA,
extraction of Sarkosyl-insoluble outer membrane pro-
teins, RNA isolation, immunofluorescence labeling, as
well as for adherence, invasion and macrophage assays,
recombinant E. coli strains were grown in LSLB supple-
mented with the EPICENTRE® Biotechnologies Copy-
Control™ Induction Solution as previously reported [96].
The epithelial cell lines HEp2 (human laryngeal
epithelium; ATCC CCL-23) and A549 (type II alveolar
lung epithelium; ATCC CCL85) were cultured as
outlined by others [97] and the murine macrophage cell
line J774A.1 (ATCC TIB-67) was grown in DMEM
medium (Mediatech, Inc) supplemented with 10% fetal
bovine serum (Invitrogen™) at 37°C and in the presence
of 7.5% CO2. Normal human bronchial epithelium
(LONZA) were expanded, cryopreserved and cultured in
an air-liquid interface system as previously described
[67-69]. Normal human bronchial epithelium (NHBE)
were grown on Transwell permeable inserts (Corning)
and their apical surfaces were exposed to air for a mini-
mum of 3 weeks prior to use in biological assays to
ensure proper cellular differentiation and the develop-
ment of functional cilia.
Recombinant DNA methodology
Standard molecular biology techniques were performed
as described elsewhere [98]. Genomic DNA was isolated
using the Invitrogen™ Easy-DNA™ kit. Plasmid DNA was
obtained with the QIAprep Spin Miniprep Kit (Qiagen).
The Failsafe™ PCR System (EPICENTRE® Biotechnolo-
gies) was used to amplify the 5.5-kb boaA gene of B.
Table 3 Strains and plasmids
Strain Description Reference
B. pseudomallei
DD503 Parental strain; polymyxin B
R zeocin
S kanamycin
S streptomycin
R [107]
DD503.boaA Isogenic boaA mutant strain of DD503; polymyxin B
R zeocin
R kanamycin
S streptomycin
R This study
DD503.boaB Isogenic boaB mutant strain of DD503; polymyxin B
R zeocin
R kanamycin
S streptomycin
R This study
DD503.boaA.
boaB
Isogenic boaA boaB double mutant strain of DD503; polymyxin B
R zeocin
R kanamycin
R streptomycin
S This study
B. mallei
ATCC23344 Wild-type strain; polymyxin B
R zeocin
S kanamycin
S [26]
ATCC23344.boaA Isogenic boaA mutant strain of ATCC23344; polymyxin B
R zeocin
R kanamycin
S This study
E. coli
EPI300 Cloning strain EPICENTRE®
Biotechnologies
S17 Strain used for conjugational transfer of suicide plasmids from E. coli to B. pseudomallei or B. mallei [108]
Plasmids
pCC1™ Cloning vector; chloramphenicol resistant (Cm
R) EPICENTRE®
Biotechnologies
pKAS46 Mobilizable suicide plasmid; kanamycin
R and ampicillin
R [109]
pCC1.3 pCC1-based plasmid control, does not confer adherence; Cm
R [102]
pSLboaA pCC1 containing the B. mallei ATCC23344 boaA gene; Cm
R This study
pSLboaAZEO pSLboaA in which a zeocin
R marker was introduced near the middle of the boaA gene; Cm
R and
zeocin
R
This study
pKASboaAZEO pKAS46 containing the insert from pSLboaAZEO; zeocin
R , ampicillin
R and kanamycin
R This study
pSLboaB pCC1 containing the B. pseudomallei DD503 boaB gene; Cm
R This study
pSLboaBZEO pSLboaB in which a zeocin
R marker was introduced near the middle of the boaB gene; Cm
R and
zeocin
R
This study
pKASboaBZEO pKAS46 containing the insert from pSLboaBZEO; zeocin
R , ampicillin
R and kanamycin
R This study
pKASboaB5’ pKAS46 containing a 0.8-kb insert which corresponds to a region located within the 5’ end of the B.
pseudomallei DD503 boaB ORF; ampicillin
R and kanamycin
R
This study
pKASboaB5’Amp
S pKASboaB5’ in which the ampicillin
R marker was removed; ampicillin
S and kanamycin
R This study
pEM7ZEO Source of the zeocin
R marker; ampicillin
R and zeocin
R Invitrogen™
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CCG CGT TTC CGT ATC-3’)a n dP 2( 5 ’-ACT CAT
ACG GCT CGC GCA TAA A-3’). This amplicon was
cloned in the vector pCC1™ using the CopyControl™
PCR Cloning Kit (EPICENTRE® Biotechnologies), yield-
ing the plasmid pSLboaA (Table 3). The 5.4-kb boaA
gene of B. pseudomallei DD503 was amplified with P3
(5’-GCT TGC CGC ACG CAA TGG CT-3’) and P4 (5’-
ATG GCG AGC GCG AAA CAT GGA AA-3’) and the
purified PCR product was used as a template in sequen-
cing reactions. The 5.9-kb boaB gene of B. pseudomallei
DD503 was generated with the Failsafe™ PCR system
using P5 (5’-TCC ATA AAT TCC CGG CGC TTG
TTG-3’)a n dP 6( 5 ’- T G TC T CG A CA T CA G CG G T
TCA CTT-3’), sequenced, and then cloned in pCC1™ as
described above, yielding the plasmid pSLboaB (Table 3).
Of note, the inserts of plasmids pSLboaA and pSLboaB
were sequenced to verify that PCR did not introduce
mutations resulting in aminoa c i d( a a )s u b s t i t u t i o n si n
the boaA and boaB gene products.
Construction of boaA isogenic mutant strains of B. mallei
and B. pseudomallei
A 0.45-kb zeocin
R cassette was introduced into a unique
NheI site located near the middle of the boaA ORF in
pSLboaA. The resulting construct, designated pSLboaA-
ZEO, was digested with BamHI and a 6-kb fragment
corresponding to the boaA ORF interrupted by the zeo-
cin
R marker was excised from an agarose gel, purified
with the High Pure PCR Product Purification Kit (Roche
Applied Science), and treated with the EPICENTRE®
Biotechnologies End-It™ DNA End Repair Kit. This
blunt DNA fragment was then subcloned into the
EcoRV site of the suicide vector pKAS46. The resulting
plasmid, pKASboaAZEO, was introduced into the E. coli
strain S17 by electroporation and subsequently trans-
ferred into B. mallei ATCC23344 or B. pseudomallei
DD503 by conjugation as reported by others [99].
Upon conjugation, B. pseudomallei colonies were first
selected for resistance to PmB (to prevent growth of
E. coli S17) and zeocin (to select strains containing the
disrupted copy of boaA in their genome). These putative
mutants were then tested for their sensitivity to kana-
mycin and resistance to streptomycin, which identified
strains that did not contain the suicide vector pKAS46
integrated in their genome. Lastly, these PmB
R zeocin
R
Kan
S Sm
R conjugants were screened by PCR using Plati-
num® Pfx DNA Polymerase (Invitrogen™)w i t ht h ep r i -
mers P7 (5’-TTG AGC ACG ACC AAC AGC AAC
GTC-3’)a n dP 8( 5 ’- C C AA T GC G GT C GA A TG A T
TGC C-3’), which led to the identification of the mutant
strain DD503.boaA. These primers yielded a PCR pro-
duct of 1.3-kb in B. pseudomallei DD503 and a larger
amplicon of 1.8-kb in the mutant. The primers P9
(5’-TAT CGC AAG GTT TGG AAC AAG GCG-3’) and
P10 (5’-ACG CCG AAT ACC CTT GAT AGC TG-3’)
were also used to further confirm gene replacement in
the B. pseudomallei mutant strain. These primers ampli-
fied DNA fragments of 5-kb in the parent strain DD503
and of 5.5-kb in the isogenic boaA mutant. After the
conjugative transfer of plasmid pKASboaAZEO into the
B. mallei strain ATCC23344, colonies shown to be
PmB
R,z e o c i n
R and Kan
S were screened by PCR with P7
and P8 as described above to identify the mutant strain
ATCC23344.boaA. Of note, the boaA genes of both iso-
genic mutant strains DD503.boaA and ATCC23344.
boaA were amplified and sequenced in their entirety to
verify proper allelic exchange and successful disruption
of boaA.
Construction of a boaB B. pseudomallei isogenic mutant
strain
The plasmid pSLboaB was digested with NheI to remove
a 162-bp fragment internal to the boaB ORF, treated
with the End-It™ DNA End Repair Kit and ligated with
the 0.45-kb zeocin
R marker to yield the construct
pSLboaBZEO. This plasmid was digested with BamHI
and a 6.2-kb fragment, which corresponds to the boaB
ORF disrupted with the zeocin
R cassette, was purified
from agarose gel slices, subcloned into the suicide plas-
mid pKAS46 and introduced into B. pseudomallei
DD503 by conjugation as described above. Conjugants
shown to be PmB
R zeocin
R Kan
S Sm
R were screened by
PCR using Platinum® Pfx DNA Polymerase (Invitrogen™)
with primers P11 (5’-AGG TGG CGAC TCA AAT
AGA ACC GT-3’)a n dP 1 2( 5 ’-GTT CGT GTT GTT
GGC TAC GGC AAT-3’) to identify the mutant strain
DD503.boaB. These primers amplified a PCR product of
1.7-kb in B. pseudomallei DD503 and of 2.0-kb in the
mutant. The primers P13 (5’-AGG TGG CGA CTC
AAA TAG AAC CGT-3’)a n dP 1 0w e r ea l s ou s e dt o
further confirm gene replacement in the B. pseudomallei
mutant strain. These primers generated amplicons of
5.2-kb and 5.5-kb in strains DD503 and DD503.boaB,
respectively. Additionally, the boaB gene of DD503.boaB
w a sa m p l i f i e da n db o t hs t r a n d so ft h eP C Rp r o d u c t
were sequenced to verify allelic exchange.
Construction of a B. pseudomallei boaA boaB double
mutant strain
A 0.8-kb PCR product, which corresponds to a region
located within the 5’end of the B. pseudomallei DD503
boaB ORF, was amplified with Platinum® Pfx DNA Poly-
merase (Invitrogen™) using primers P14 (5’-CTC GGG
CTC AAT AAC ATG GC-3’)a n dP 1 5( 5 ’-CGG AAT
TCC GGT TCG TGT TGT TGG CT-3’; EcoRI site under-
lined). This amplicon was digested with EcoR1 and direc-
tionally cloned into the EcoRV and EcoR1 sites of the
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This construct was digested with ApaLI to remove a 0.8-
kb fragment corresponding to the ampicillin-resistance
marker of pKAS46 and the resulting plasmid, pKASboa-
B5’Amp
S , was introduced into the B. pseudomallei
mutant strain DD503.boaA by conjugation as described
above. Conjugants shown to be PmB
R zeocin
R Kan
R Sm
S
were screened by PCR using the MasterAmp™ Extra-Long
PCR kit (EPICENTRE® Biotechnologies) with primers P13
and P10 to identify the mutant strain DD503.boaA.boaB.
These primers amplified PCR products of 5.2-kb in B.
pseudomallei DD503 as well as in the single mutant
DD503.boaA, and of 11.0-kb in the double mutant strain
DD503.boaA.boaB. These results indicated that the boaB
gene in DD503.boaA.boaB had been disrupted by integra-
tion of the entire pKASboaB5’Amp
S plasmid into the gen-
ome of B. pseudomallei.
Quantitative reverse-transcriptase PCR (qRT-PCR)
Total RNA was extracted from 10
8 bacteria with the
RNeasy Kit (Qiagen). One μg of total RNA was treated
with RQ1 RNAse-Free DNase (Promega) and reverse
transcribed with Improm II™ Reverse transcriptase (Pro-
mega) using random hexamers (Invitrogen™)u n d e rt h e
manufacturer’s recommended conditions. PCR quantifi-
cation of specific cDNA levels was performed using a
LightCycler® (Roche Applied Science) rapid fluorescence
temperature cycler as reported elsewhere [100]. Briefly,
amplification was performed in a 10 μlf i n a lv o l u m e
containing 50 mM Tris (pH 8.3), 3 mM MgCl2,4 . 5μg
of bovine serum albumin, 200 μM deoxynucleotide tri-
phosphates, a 1:10,000 dilution of SYBR® Green I (Mole-
cular Probes, Inc.), 1 μM each primer, and 1 unit of
Platinum® Taq DNA Polymerase (Invitrogen™). Amplifi-
cation was performed for 40 cycles, with each run con-
sisting of an initial melting at 95°C for 2 minutes,
followed by melting, annealing, extension, and acquiring
temperatures specific to each primer set. Serial dilutions
of a representative template cDNA were amplified using
each primer set to create a standard curve. Particular
transcript levels in experimental samples were calculated
by comparison to the corresponding standard curve. All
calculated values for the boaA and boaB genes are nor-
malized to either the Burkholderia recA or E. coli recA
levels. A primer set for Borrelia burgdorferi recA [100]
was used as a non-Burkholderia control to further
demonstrate primer specificity (control in Fig 4). Nega-
tive controls in which the reverse transcriptase enzyme
was not added to reaction mixtures were included in all
experiments (data not shown). The boa and recA tran-
scripts were amplified from the same sets of samples.
The primer sets used were: boaAF (5’-ATC GCG AAC
AAT GCG AAC GAT GTC-3’)a n db o a A R( 5 ’-AAG
C G AA T AA G CC T GA C CT G CG A T - 3 ’), boaBF
(5’-AAT GCC GTA GCC AAC AAC ACG AAC-3’) and
boaBR (5’-TCG TCG AGT AAA GTT GCG AAC CGT-
3’), recABURKF (5’-CAC GAA CTG CCT CGT GAT
CTT CAT-3’)a n dr e c A B U R K R( 5 ’-AAA TGC CTT
CGC CGT ACA GGA TGT-3’), recACOLIF (5’-ATG
GCT ATC GAC GAA AAC-3’) and recACOLIR (5’-
GGT TTT ACC GGA AGA TTC C-3’), and recABbF
(5’-GTC GAT CTA TTG TAT TAG ATG AGG CTC
TCG-3’) and recABbR (5’-GCC AAA GTT CTG CAA
CAT TAA CAC CTA AAG-3’).
Nucleotide sequence analyses
PCR products and plasmids were sequenced at the Uni-
versity of Michigan Sequencing Core. Chromatograms
were assembled using the Sequencher 4.9 software
(Gene Codes Corporation). The nucleotide sequences of
the B. pseudomallei DD503 boaA (EF423807) and boaB
(EF423808) genes were deposited in GenBank under the
indicated accession number.
Bioinformatic Analyses
Sequence analyses were performed using Vector NTI
(Invitrogen) and the various online tools available
through the ExPASy Proteomics Server (http://au.
expasy.org/). Signal sequence cleavage sites were deter-
mined using the SignalP 3.0 server (http://www.cbs.dtu.
dk/services/SignalP/). The B. mallei ATCC23344 boaA
gene product (locus tag BMAA0649) was identified by
searching the genome of the organism for the presence
of a YadA-like C-terminal domain (Pfam database num-
ber PF03895) through the NCBI genomic BLAST service
using the tblastn and blastp programs (http://www.ncbi.
nlm.nih.gov/sutils/genom_table.cgi). The other boaA and
boaB gene products described in this study were identi-
fied by using the predicted aa sequence of the B. mallei
ATCC23344 BoaA protein to search the genomes of the
B. mallei as well as B. pseudomallei strains available
through the NCBI genomic BLAST service utilizing the
tblastn and blastp programs. Structural features of the
Boa proteins (e.g. helical regions, b-strands) were identi-
fied using the PSIPRED Protein Structure Prediction
Server (http://bioinf.cs.ucl.ac.uk/psipred/).
Epithelial cell adherence assays
Quantitative attachment assays were performed as pre-
viously described by our laboratory [61,67]. Mono-
l a y e r so fA 5 4 9a n dH E p 2c e l l sa n dc u l t u r e so fN H B E
were infected with B. mallei, B. pseudomallei or
recombinant E. coli strains at a MOI of 100. Duplicate
assays were repeated on at least 3 occasions for each
strain, and adherence is expressed as the percentage (±
standard error) of bacteria attached to epithelial cells
relative to the inoculum. Statistical analyses were per-
formed using the Mann-Whitney test (GraphPad Prism
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cally significant.
Biofilm and bactericidal assays
These experiments were performed as previously
described [96,101,102]. We used 50% and 25% normal
human serum in bactericidal assays with B. pseudomallei
and B. mallei, respectively.
Macrophage survival assays
Plate-grown bacteria were suspended in 5-ml of sterile
PBS supplemented with 0.15% gelatin (PBSG) to a den-
sity of 10
9 CFU/ml. These suspensions were used to
infect two identical sets of duplicate monolayers of
J774A.1 cells (10
5 cells/well; 24-well tissue culture plate)
at an MOI of 10. The inoculated tissue culture plates
were centrifuged (5-min, 165 × g) and incubated for 1-
hr at 37°C, time after which the medium covering the
monolayers was replaced with fresh tissue culture med-
ium containing 50 μg/ml gentamicin. After a 2-hr incu-
bation (i.e. 3-hr post infection), the wells of one tissue
culture plate were washed, J774A.1 cells were lysed with
a solution containing Saponin, and serial dilutions of the
well contents were spread onto agar plates to determine
the number of bacteria phagocytosed by the macro-
phages. The wells of the other tissue culture plate were
washed once, fresh medium without antibiotics
was added, and the plate was incubated for an additional
5-hr. Following this incubation (i.e. 8-hr post-infection),
the wells were processed as described above in order to
enumerate bacteria. These experiments were repeated
on at least 3 separate occasions. Statistical analyses were
performed using the Mann-Whitney test (GraphPad
Prism software) and P values < 0.05 are reported as sta-
tistically significant.
Epithelial cell invasion and survival assays
These experiments were performed as described above
for macrophage survival assays with some modifications.
Specifically, epithelial cells were infected with an MOI
of 100. The inoculated tissue culture plates were centri-
fuged and incubated for 3-hr at 37°C, time after which
the medium covering the monolayers was replaced with
fresh tissue culture medium containing 50 μg/ml genta-
micin. After a 2-hr incubation (i.e. 5-hr post infection),
the wells of one tissue culture plate were washed and
processed to enumerate intracellular bacteria as
described above. The wells of the other tissue culture
plate were washed once, fresh medium without antibio-
tics was added to wells, and the plate was incubated for
an additional 3-hr. Following this incubation (i.e. 8-hr
post-infection), the wells were processed as described
above. These experiments were repeated on at least 3
separate occasions. Statistical analyses were performed
using the Mann-Whitney test (GraphPad Prism soft-
ware) and P values < 0.05 are reported as statistically
significant
Protein preparations, western blot, and antibody
production
Sarkosyl-insoluble OM proteins were obtained as pre-
viously described by Carlone et al [103]. The methods used
to prepare whole cell lysates and perform western blot
experiments are described elsewhere [61,62,67,104,105]. To
obtain antibodies directed against BoaA, the peptide PEPA
(NYLGGLFGFGPQTSMANWGDSSN) was synthesized
and conjugated to maleimide-activated keyhole limpet
hemocyanin (mcKLH, Thermo Scientific) under the manu-
facturer’s recommended conditions. The sequence of
PEPA corresponds to residues 78-100 of B. pseudomallei
DD503 BoaA and encompasses aa 79-101 of B. mallei
ATCC23344 BoaA (underlined residues in the PEPA
sequence being perfectly conserved). The mcKLH-PEPA
conjugate was emulsified in Freund’s adjuvants and used to
immunize female BALB/c mice as previously reported
[106]. BoaB-specific antibodies were obtained by immuniz-
ing mice with mcKLH conjugated to the synthetic peptide
PEPB (GWLLGTTSQTTDPGPLYPGPGAENN), which
specifies aa 131-155 of B. pseudomallei DD503 BoaB.
These animal studies were performed in compliance with
institutional, as well as governmental, rules and regulations.
Immunofluorescence labeling of E. coli and microscopy
Plate-grown bacteria were suspended in 5-ml of sterile
PBSG to a density of 10
8 CFU/ml. Portions of these sus-
pensions were spotted onto glass slides and dried using
a warming plate. The slides were fixed with PBSG sup-
plemented with 4% paraformaldehyde for 30-min at
room temperature, washed with PBS supplemented with
0.05% Tween 20 (PBST), and blocked overnight at 4°C
using PBST supplemented with 10% goat serum
(SIGMA-ALDRICH®). Next, bacteria were probed for 1-
hr at room temperature with murine a-BoaA or a-BoaB
antibodies diluted (1:200) in PBST supplemented with
10% goat serum. After this incubation, the slides were
washed with PBST to remove unbound antibodies and
incubated for 30-min at room temperature with a goat
a-mouse antibody labeled with Alexa Fluor® 546 (Mole-
cular Probes, Inc) and diluted (1:400) in PBST supple-
mented with 10% goat serum. Following this incubation,
the slides were washed with PBST to remove unbound
antibody and bacterial cells were stained using the
nucleic acid dye DAPI (Molecular Probes, Inc). Slides
were mounted with SlowFade® reagent (Invitrogen™)a n d
examined by microscopy using a Zeiss LSM 510 Meta
confocal system.
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